Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (6 thèses dirigées)
Délais de RDV courts dans la région
73.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Implication de la vasopressine dans l'hypoperfusion tissulaire au cours du choc cardiogénique compliquant l'infarctus du myocarde
2020Doctorant·e : Philippe Gaudard
Cartographie photoacoustique de l’hypoxie tissulaire après un infarctus du myocarde chez la souris
2020Doctorant·e : Hélène David
Réponses hémodynamique et hormonale au pneumopéritoine, au cours de la coelioscopie : rôle de la vasopressine et du gaz effecteur
1999Doctorant·e : Claude Mann
Utilisation de la buprénorphine dans les douleurs non cancéreuses
1999Doctorant·e : Franck Crespin
Gestion des appels pour douleurs thoraciques au Centre 15 de l'Hérault. Recherche d'une optimisation de la prise en charge de l'infarctus du myocarde
1998Doctorant·e : Laurent Devime
Etude comparée des effets de l'alimentation entérale sur les valeurs du pHi et du gradient tonométrique de PCO2 ([delta] PCO2)
1997Doctorant·e : Michel Escriva
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
2
2 articles ont été cités au moins 2fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
21
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
3
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
1
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Compliance with ESAIC guidelines for fibrinogen concentrate prescription in cardiac surgery: a multicentre French cohort study
2025ArticleBMC Anesthesiology
End-tidal carbon dioxide changes induced by passive leg raising can predict fluid responsiveness in patients on veno-arterial extracorporeal membrane oxygenation: a prospective, interventional study
2025ArticleAnnals of Intensive Care
Neuropeptide therapeutics to repress lateral septum neurons that disable sociability in an autism mouse model
2024ArticleCell Reports Medicine
Impact of a bundle of care (intravenous iron, erythropoietin and transfusion metabolic adjustment) on post-operative transfusion incidence in cardiac surgery: a single-centre, randomised, open-label, parallel-group controlled pilot trial
2024ArticleThe Lancet Regional Health - Europe
Early temporary mechanical circulatory support for cardiogenic shock: real-life data from a regional cardiac assistance network
2024ArticleThe Journal of Heart and Lung Transplantation
Impact of Red Blood Cell Transfusion on In-hospital Mortality of Isolated Coronary Artery Bypass Graft Surgery
2023ArticleAnnals of Surgery
Cost Analysis of Aprotinin Reintroduction in French Cardiac Surgery Centres: A Real-World Data-Based Analysis
2023ArticleAdvances in Therapy
Involvement of Vasopressin in Tissue Hypoperfusion during Cardiogenic Shock Complicating Acute Myocardial Infarction in Rats
2023ArticleInternational Journal of Molecular Sciences
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR PASCAL COLSON
2 RUE DE FRETAY, 91140 VILLEJUST
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Circulation · 2020
Background: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used to treat cardiogenic shock. However, VA-ECMO might hamper myocardial recovery. The Impella unloads the left ventricle. This study aimed to evaluate whether left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO was associated with lower mortality. Methods: Data from 686 consecutive patients with cardiogenic shock treated with VA-ECMO with or without left ventricular unloading using an Impella at 16 tertiary care centers in 4 countries were collected. The association between left ventricular unloading and 30-day mortality was assessed by Cox regression models in a 1:1 propensity score–matched cohort. Results: Left ventricular unloading was used in 337 of the 686 patients (49%). After matching, 255 patients with left ventricular unloading were compared with 255 patients without left ventricular unloading. In the matched cohort, left ventricular unloading was associated with lower 30-day mortality (hazard ratio, 0.79 [95% CI, 0.63–0.98]; P =0.03) without differences in various subgroups. Complications occurred more frequently in patients with left ventricular unloading: severe bleeding in 98 (38.4%) versus 45 (17.9%), access site–related ischemia in 55 (21.6%) versus 31 (12.3%), abdominal compartment in 23 (9.4%) versus 9 (3.7%), and renal replacement therapy in 148 (58.5%) versus 99 (39.1%). Conclusions: In this international, multicenter cohort study, left ventricular unloading was associated with lower mortality in patients with cardiogenic shock treated with VA-ECMO, despite higher complication rates. These findings support use of left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO and call for further validation, ideally in a randomized, controlled trial.
Critical care medicine · 2002
Arthritis research & therapy · 2009
Abstract Introduction Reactivation of hepatitis B virus (HBV) infection in patients with past infection has been described in 5% to 10% of individuals undergoing immunosuppressive therapies. No data are available to date on the outcome of patients treated by tumour necrosis factor-alpha (TNFα) inhibitors for chronic arthritis with a serological pattern of past HBV infection. The aim of our study was to monitor HBV markers in HBV surface antigen (HBsAg)-negative/anti-HBcAb-positive patients treated with a TNFα inhibitor for inflammatory arthritides. Methods Twenty-one HBsAg-negative/anti-HBcAb-positive patients were included. HBV serological patterns were compared with those determined before starting TNFα inhibitors. Serum HBV DNA testing by polymerase chain reaction was additionally performed. Spearman correlation analysis was used and P < 0.05 was chosen as the significance threshold. Results Before starting therapy, mean anti-HBsAb titre was 725 IU/L, no patient had an anti-HBsAb titre <10 IU/L, and 18 patients had an anti-HBsAb >100 IU/L. At a mean time of 27.2 months following therapy introduction, mean anti-HBsAb titre was 675 IU/L and anti-HBsAb titre remained >100 IU/L in 17 patients. There was a strong correlation between the first and second anti-HBsAb titres (r = 0.98, P = 0.013). Moreover, no patient had an anti-HBsAb titre below 10 IU/L or HBV reactivation (HBsAg seroreversion or positive HBV DNA detection). However, the anti-HBsAb titre decreased by more than 30% in 6 patients. The mean anti-HBsAb titre at baseline was significantly lower (P = 0.006) and the mean duration of anti-TNFα therapy, although non-significant (P = 0.09), was longer in these six patients as compared to patients without a decrease in anti-HBsAb titre. Conclusions Anti-TNFα treatments are likely to be safe in patients with past hepatitis B serological pattern. However, the significant decrease of anti-HBsAb titre observed in a proportion of patients deserves HBV virological follow-up in these patients, especially in those with a low anti-HBsAb titre at baseline.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Cell reports. Medicine · 2024 · Journal Article
Borie AM, Dromard Y, Chakraborty P, Fontanaud P, et al.
Annals of surgery · 2023 · Observational Study
Colson PH, Gaudard P, Meunier C, Seguret F
The Annals of thoracic surgery · 2021 · Journal Article
Saour M, Zeroual N, Aubry E, Blin C, et al.
Future science OA · 2021 · Journal Article
Kalmanovich E, Battistella P, Rouviere P, Albat B, et al.
Frontiers in cardiovascular medicine · 2020 · Journal Article
David H, Ughetto A, Gaudard P, Plawecki M, et al.
International journal of cardiology · 2020 · Journal Article
Leclercq F, Lonjon C, Marin G, Akodad M, et al.
BMC infectious diseases · 2019 · Journal Article
Gaudard P, Saour M, Morquin D, David H, et al.
Journal of thoracic disease · 2016 · Comment
Gaudard P, Colson P
Internal medicine (Tokyo, Japan) · 2010 · Case Reports
Roubille F, Maxant G, Serre I, Colson P, et al.
Critical care medicine · 2009 · Journal Article
Ryckwaert F, Virsolvy A, Fort A, Murat B, et al.
BMC anesthesiology · 2025 · Journal Article
Longrois D, Albaladejo P, Bedague D, Ouattara A, et al.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025 · Journal Article
Colson PH, Gaudriot B, Provenchère S, Rozec B, et al.
The Lancet regional health. Europe · 2024 · Journal Article
Saour M, Blin C, Zeroual N, Mourad M, et al.
The Lancet regional health. Europe · 2024 · Journal Article
Saour M, Blin C, Zeroual N, Mourad M, et al.
Intensive care medicine · 2019 · Journal Article
Lagier D, Fischer F, Fornier W, Huynh TM, et al.
Pharmacological research · 2016 · Journal Article
Colson PH, Virsolvy A, Gaudard P, Charrabi A, et al.
Arthritis research & therapy · 2009 · Journal Article
Charpin C, Guis S, Colson P, Borentain P, et al.
Frontiers in microbiology · 2014 · Journal Article
Romano-Bertrand S, Frapier JM, Calvet B, Colson P, et al.
Expert review of cardiovascular therapy · 2018 · Journal Article
Kalmanovich E, Audurier Y, Akodad M, Mourad M, et al.
Advances in therapy · 2023 · Multicenter Study
Colson P, Fellahi JL, Gaudard P, Provenchère S, et al.
A perioperative surgeon-controlled open-lung approach versus conventional protective ventilation with low positive end-expiratory pressure in cardiac surgery with cardiopulmonary bypass (PROVECS): study protocol for a randomized controlled trial
Abstract Background Postoperative pulmonary complications (PPCs) are frequent after on-pump cardiac surgery. Cardiac surgery results in a complex pulmonary insult leading to high susceptibility to perioperative pulmonary
Supplementary data: Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of 10 patients.docx
<b>Supplementary Table 1</b>. Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of 10 patients Baseline characteristics of the patients.
End-tidal carbon dioxide changes induced by passive leg raising can predict fluid responsiveness in patients on veno-arterial extracorporeal membrane oxygenation: a prospective, interventional study
Abstract Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used in patients with cardiogenic shock. It results in cardiopulmonary shunting with reduced native cardiac output. Volume e
A perioperative surgeon-controlled open-lung approach versus conventional protective ventilation with low positive end-expiratory pressure in cardiac surgery with cardiopulmonary bypass (PROVECS): study protocol for a randomized controlled trial
Abstract Background Postoperative pulmonary complications (PPCs) are frequent after on-pump cardiac surgery. Cardiac surgery results in a complex pulmonary insult leading to high susceptibility to perioperative pulmonary
Supplementary data: Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of 10 patients.docx
<b>Supplementary Table 1</b>. Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of 10 patients Baseline characteristics of the patients.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
European heart journal. Acute cardiovascular care · 2024 · Multicenter Study
Beer BN, Kellner C, Goßling A, Sundermeyer J, et al.
Circulation · 2020 · Journal Article
Schrage B, Becher PM, Bernhardt A, Bezerra H, et al.
Intensive care medicine · 2003 · Journal Article
Ryckwaert F, Alric P, Picot MC, Djoufelkit K, et al.
Critical care medicine · 2002 · Journal Article
Ryckwaert F, Boccara G, Frappier JM, Colson PH
Trials · 2018 · Clinical Trial Protocol
Lagier D, Fischer F, Fornier W, Fellahi JL, et al.